Bayer exec says he hopes EU takes time to improve drug rules reform
By Ludwig Burger and Patricia Weiss
FRANKFURT, March 24 (Reuters) -The head of Bayer's BAYGn.DE pharmaceuticals unit said he hopes a recent European Union decision to postpone rule changes for the pharmaceutical industry means that a cut in intellectual drug property protection will be reconsidered.
"I hope that this delay means that there is an opportunity that this draft... is not the final version," the head of Bayer's pharmaceuticals unit, Stefan Oelrich, told Reuters on Friday.
The European Commission said this week that the publication of a first draft of a planned revision of drug legislation in the bloc would be "slightly later" than March 29, as initially planned.
A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection.
"The duration of data exclusivity, which may be reduced, could actually have a catastrophic impact for Europe," said Oelrich.
Shaving one or two years off the exclusivity period could mean that pharma companies pull the plug on certain development projects for the region, he added.
He said the intentions of Brussels lawmakers - improving patient access to innovative drugs while making the European pharma sector more competitive - were noble but any shortening of intellectual property protection would have the opposite effect.
Reporting by Ludwig Burger; editing by Jonathan Oatis
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。